To know the efficacy of Amritabhallataka with virechana vs koshthshodhana in patients of Amavata (Rheumatoid Arthritis)

A COMPARATIVE STUDY TO EVALUATE THE EFFECT OF AMRITA BHALLATAKA WITH VIRECHANA VS KOSHTHASHODHANA IN THE MANAGEMENT OF AMAVATA ( RHEUMATOID ARTHRITIS), A RANDOMISED CLINICAL STUDY

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/03/050182

Enrollment

Registered

2023-03-01

Start date

Unknown

Completion date

Unknown

Last updated

2023-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M058- Other rheumatoid arthritis with rheumatoid factor

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients having the clinical manifestation of Amavata (RA) according to Ayurvedic classics - Sandhishool (pain), shoth (swelling), sparshasahata (tenderness) and stabdhata (stiffness),Vrishichikadansavata vedana(pain like scorpion sting), Agnimandya (poor digestion) , Aruchi(anorexia), Gaurav(Feeling of heaviness of body),Utsaha Hani(lack of interest),Mukha vairasya(Perverted taste). 2. Diagnosed cases of amavata (RA) 3. Patients willing to participate in the research study.

Exclusion criteria

Exclusion criteria: 1) Patients with other systemic complications of RA like RHD, Rheumatic fever, pleural â?? pericardial disease. 2) Patients with poorly controlled Hypertension ( >160/100 mm of Hg) 3) Patients with Diabetes Mellitus {B.S. (F) > 126 mg% and / or B.S. (2 hr. PP) >200 mg% OR HbA1c > 6.5%} 4) Patients diagnosed with other arthritis like gouty arthritis, tuberculous arthritis, etc. 5) Patients who are unable to walk without support and / or confined to wheel chair. 6) H/o hypersensitivity to any of the trial drugs or their ingredients. 7) Patients on prolonged ( > 6 weeks) medication with antidepressants, anticholinergic, etc. or any other drugs that may have an influence on the outcome of the study. 8) Pregnant / lactating woman. 9) Patients who have completed participation in any other clinical trial during the past 6 months. 10) Patients allergic to any content of the drug.

Design outcomes

Primary

Measure	Time frame
1. To provide relief in other cardinal symptoms of Amavata (RA) â?? shoth (swelling), sparshasahata(tenderness) and Stabdhata (stiffness). 2. To observe changes in the values of E.S.R. and C.R.P. Timepoint: BASELINE , 6 WEEKS	—

Secondary

Measure	Time frame
1. To Improve the quality of life of Amavata patients. Timepoint: BASELINE , 6 WEEKS	—

Countries

India

Contacts

Public ContactDR RAMA KANT YADAVA

ALL INDIA INSTITUTE OF AYURVEDA

jonahdr@gmail.com9448262298

Outcome results